Biosynth Unveils Expanded GMP Bioconjugation Facility in Berlin to Advance Next-Generation Therapeutics
Biosynth, a global leader in providing essential raw materials and services for the life sciences and diagnostics industries, has officially inaugurated a major expansion of its GMP bioconjugation facility in Berlin. This strategic enhancement of its existing site marks a significant milestone in the company’s mission to support the development and production of advanced therapeutic and diagnostic products.
The newly opened facility is a critical component of Biosynth’s broader global manufacturing network, designed to meet the increasing demand for specialized bioconjugation services. These services play a crucial role in the development of next-generation conjugate vaccines, antibody-drug conjugates (ADCs), activated polyethylene glycols (PEGs), and polymer-based drug delivery systems—therapeutic modalities that are rapidly gaining prominence in the pharmaceutical and biotechnology sectors.
With the completion of the expansion, Biosynth is now equipped to offer scalable, flexible, and GMP-compliant bioconjugation solutions to its customers around the world. The new suite includes state-of-the-art class D and class C cleanrooms, reflecting the company’s commitment to quality and regulatory excellence. These enhancements allow Biosynth to better support customers from early-stage development through to commercial-scale manufacturing.
Strengthening Capabilities to Meet Growing Demand
Thomas Eisele, Chief Operations Officer at Biosynth, highlighted the importance of the new facility in meeting the evolving needs of its customer base:
“We are thrilled to officially open the new expansion to our bioconjugation facility in Berlin, which represents a significant enhancement to our existing operations. This suite enables the scalable, diverse, high-quality conjugation services that our customers need to advance to the next generation of therapies.”
Eisele’s comments underscore Biosynth’s recognition of the critical role that bioconjugation plays in today’s therapeutic landscape. The ability to offer reliable and high-quality conjugation services is vital for companies working on complex biologics, such as targeted cancer therapies and innovative vaccine platforms.
Frank Leenders, General Manager of the Berlin site, elaborated on how the expansion aligns with the growth of both the company and its clientele:
“The construction of our new facility, including class D and C cleanrooms, represents a natural evolution of our Berlin operation—in many ways, we are growing alongside our customers. The additional refurbishment of our existing facility enhances our GMP manufacturing capabilities, reinforcing our commitment to meeting the evolving needs of our customers.”
By investing in infrastructure that scales with customer needs, Biosynth continues to position itself as a long-term partner in product development and commercialization.
A Full-Service Bioconjugation Partner
Beyond the physical expansion, the Berlin facility now represents a comprehensive bioconjugation hub—supporting a full range of activities from process development and analytical support to GMP-grade manufacturing. This integrated approach ensures greater continuity, consistency, and speed for clients moving through the various stages of drug and diagnostic product development.
Marie Leblanc, Executive Vice President of Life Sciences at Biosynth, emphasized the strategic significance of this end-to-end support:
“Conjugation chemistry, advanced polymers and bioconjugation production are critical areas for many of our life science customers. Being able to support projects fully, from initial bioconjugate process development to commercial GMP supply, enables us to provide specialized conjugation solutions for diagnostics and therapeutics—strengthening our position as a trusted partner in the life science industry.”
Biosynth’s capabilities now span a wide spectrum of conjugation services, including custom synthesis of linkers and crosslinkers, development of activated PEGs, and functionalized polymers tailored for controlled drug delivery applications. These materials are central to the success of many modern biopharmaceuticals, offering enhanced specificity, improved pharmacokinetics, and reduced systemic toxicity.
